Radiopharmaceutical therapy or targeted radionuclide therapy (TRT) is a well-established
class of cancer therapeutics that includes a growing number of FDA-approved drugs and a …

During the last decades, new radionuclide-based targeted therapies have emerged as
efficient tools for cancer treatment. Targeted radionuclide therapies (TRTs) are based on a …

Radiopharmaceutical therapy (RPT) is emerging as a safe and effective targeted approach
to treating many types of cancer. In RPT, radiation is systemically or locally delivered using …

Radionuclide therapy (RNT) based on the concept of delivering cytotoxic levels of radiation
to disease sites is one of the rapidly growing fields of nuclear medicine. Unlike conventional …

The growing interest in targeted radionuclide therapy (TRT) for a broad range of applications
is shared by a diverse group of medical professionals, including but not limited to physicians …

We read with interest the letter by Giammarile et al.[1] addressing our editorial in which we
proposed that the European Medicines Agency should allow the option of a dosimetrybased …

A comprehensive, mechanistic understanding of radiobiological phenomena that can be
integrated within the broader context of cancer biology offers the prospect of transforming …

Radionuclide therapy (RNT) stands on the delivery of radiation to tumors or non-tumor target
organs using radiopharmaceuticals that are designed to have specific affinity to targets. RNT …

A search in PubMed revealed that 72 radionuclides have been considered for molecular or
functional targeted radionuclide therapy. As radionuclide therapies increase in number and …

Targeted radionuclide therapy has become increasingly prominent as a nuclear medicine
subspecialty. For many decades, treatment with radionuclides has been mainly restricted to …